A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFolfirinox versus mFolfirinox alone in Patients with Resected Pancreatic Ductal Adenocarcinoma Protocol G044479

Clinical Trial Grant

Duke Scholars

Principal Investigator Daniel Philip Nussbaum Surgical Oncology

Administered By

Surgical Oncology

Awarded By

Genentech, Inc.

Start Date

November 9, 2023

End Date

November 30, 2033

Administered By

Surgical Oncology

Awarded By

Genentech, Inc.

Start Date

November 9, 2023

End Date

November 30, 2033